EP Patent

EP4069254A4 — SOLID ORAL DOSAGE FORMS WITH DECITABINE AND CEDAZURIDINE

Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2023-11-29 · 2y expired

What this patent protects

Patent listed against cedazuridine.

Drugs covered by this patent

Patent Metadata

Patent number
EP4069254A4
Jurisdiction
EP
Classification
—
Expires
2023-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.